News & Events

CLEW Named to Newsweek’s List of World’s Best Digital Health Companies 2024

Boston, MA (April 26, 2024) – CLEW, a clinical intelligence and predictive surveillance company, announced today that it has been named to Newsweek’s list of the World’s Best Digital Health Companies for 2024 within the Data Analytics category. This prestigious award was presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider.

“We’re honored to be part of Newsweek’s World’s Best Digital Health Companies, as it provides further validation of our technology’s transformational capabilities,” said Paul Roscoe, CEO of CLEW. “At CLEW, we believe AI that is rigorously trained, – clinically validated and regulated has the capacity to revolutionize the future of care delivery. By leveraging machine learning-based prediction models and rules-based best practices, clinicians can focus on delivering top-of-license care, leading to better patient outcomes.”

The World’s Best Digital Health Companies 2024 ranking lists the top 400 companies from over 35 different countries. The winners were ranked across seven market segments: Data Analytics, Diagnostics, Health Records, Medical Management, Prevention, Telehealth and Treatment.

The top list is based on three pillars: financial performance, impact and online engagement. For each area, Statista analyzed data from a range of sources assessing each company’s financial strength, expertise of the leadership team and quality of its product or service as well as engagement by users:

  • Financial Performance: Statista analyzed financial data from publicly available sources. CLEW’s platform is now deployed at a growing number of US hospitals from large academic teaching hospitals to rural community hospitals. New deployments are also being brought on-line in European hospitals.

  • Impact: Statista cooperated with data and market intelligence company HolonIQ to assess a company in different impact dimensions, encompassing factors such as the quality and uniqueness of their product/service, as well as the expertise of their leadership team. CLEW’s system of AI-derived models for predicting patient deterioration is the first of its kind to achieve FDA clearance as a class II medical device. The novel system has also been proven in a peer-reviewed study to be five times more accurate and generate 50-times fewer alarms than other telemedicine and bedside monitoring systems.

  • Online Engagement: Statista analyzed traffic data from company websites and apps to assess the engagement of users with their product/service.

Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of, the leading data and business intelligence portal that provides statistics, relevant business data, and various market and consumer studies and surveys.

About CLEW Medical, Inc.

CLEW offers the first FDA-cleared, class II medical device, AI-based clinical predictive models for critical care as a part of its intelligent clinical surveillance platform. Its ability to offer accurate, predictive insights around patient deterioration allows health systems to optimize patient interventions, decreasing mortality and reducing complications & readmissions. Its proprietary models offer an optimal balance of precision and sensitivity, which results in fewer high-risk notifications, reducing alarm fatigue amongst providers and clinicians. For more information, visit

Matter Health for CLEW Medical
Matt Robbins
T: 617.874.5203

Request a Demo

"*" indicates required fields